Print

Active Biotech AB Interim report January-June 2014

2014-08-07

Laquinimod

  • On May 23, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) reaffirmed its negative opinion on the market application for laquinimod (Nerventra®)
  • CHMP confirmed that the risks observed in animal studies do not prevent a registration for treatment in humans
  • The ongoing US pivotal clinical study CONCERTO is continuing according to plan. The results are expected in 2016

Tasquinimod

  • The Phase III study 10TASQ10 is proceeding according to plan

ANYARA

  • Development program for further clinical development outlined in collaboration with regulatory authorities
  • All project activities will be put on hold until further notice


Paquinimod (57-57)

  • In June 2014, data related to the drug candidate paquinimod for the treatment of systemic sclerosis was presented at the scientific conference "EULAR Annual European Congress of Rheumatology"

ISI

  • Expansion of the patent portfolio
  • CD selection expected in 2015

Financial summary

MSEK April - June January - June Full Year
2014 2013 2014 2013 2013
Net sales 2.7 2.5 4.9 5.0 116.0
Operating loss -57.9 -79.5 -117.2 -156.5 -209.0
Loss for the period -57.7 -81.2 -117.9 -159.2 -212.1
Loss per share (SEK) -0.77 -1.08 -1.57 -2.18 -2.87

For further information, please contact:


Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95

Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

The report is also available at www.activebiotech.com

pdfActive Biotech AB Interim report January-June 2014



Back